Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 : JACC State-of-the-Art Review
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved..
Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Journal of the American College of Cardiology - 78(2021), 16 vom: 19. Okt., Seite 1635-1654 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Talasaz, Azita H [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.10.2021 Date Revised 07.12.2022 published: Print UpdateOf: medRxiv. 2021 May 04;:. - PMID 33972948 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jacc.2021.08.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331904268 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331904268 | ||
| 003 | DE-627 | ||
| 005 | 20231225214511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2021.08.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM331904268 | ||
| 035 | |a (NLM)34649702 | ||
| 035 | |a (PII)S0735-1097(21)05970-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Talasaz, Azita H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 |b JACC State-of-the-Art Review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a UpdateOf: medRxiv. 2021 May 04;:. - PMID 33972948 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a fibrate | |
| 650 | 4 | |a lipid-modulating agent | |
| 650 | 4 | |a niacin | |
| 650 | 4 | |a omega-3 | |
| 650 | 4 | |a statin | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Esters |2 NLM | |
| 650 | 7 | |a Fatty Acids, Omega-3 |2 NLM | |
| 650 | 7 | |a Fibric Acids |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a Lipid Regulating Agents |2 NLM | |
| 650 | 7 | |a Sulfhydryl Compounds |2 NLM | |
| 650 | 7 | |a Niacin |2 NLM | |
| 650 | 7 | |a 2679MF687A |2 NLM | |
| 650 | 7 | |a dalcetrapib |2 NLM | |
| 650 | 7 | |a 3D050LIQ3H |2 NLM | |
| 700 | 1 | |a Sadeghipour, Parham |e verfasserin |4 aut | |
| 700 | 1 | |a Aghakouchakzadeh, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Dreyfus, Isaac |e verfasserin |4 aut | |
| 700 | 1 | |a Kakavand, Hessam |e verfasserin |4 aut | |
| 700 | 1 | |a Ariannejad, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Aakriti |e verfasserin |4 aut | |
| 700 | 1 | |a Madhavan, Mahesh V |e verfasserin |4 aut | |
| 700 | 1 | |a Van Tassell, Benjamin W |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Monreal, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Vaduganathan, Muthiah |e verfasserin |4 aut | |
| 700 | 1 | |a Fanikos, John |e verfasserin |4 aut | |
| 700 | 1 | |a Dixon, Dave L |e verfasserin |4 aut | |
| 700 | 1 | |a Piazza, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Sahil A |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatt, Deepak L |e verfasserin |4 aut | |
| 700 | 1 | |a Lip, Gregory Y H |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, Gregg W |e verfasserin |4 aut | |
| 700 | 1 | |a Krumholz, Harlan M |e verfasserin |4 aut | |
| 700 | 1 | |a Libby, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Goldhaber, Samuel Z |e verfasserin |4 aut | |
| 700 | 1 | |a Bikdeli, Behnood |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American College of Cardiology |d 1987 |g 78(2021), 16 vom: 19. Okt., Seite 1635-1654 |w (DE-627)NLM012608602 |x 1558-3597 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2021 |g number:16 |g day:19 |g month:10 |g pages:1635-1654 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacc.2021.08.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2021 |e 16 |b 19 |c 10 |h 1635-1654 | ||